Published in Cardiovascular Device Liability Week, January 2nd, 2005
According to the report from the United States, "Since Mg2+-ATP is the controlling factor for the rate-limiting enzyme in the cholesterol biosynthesis sequence that is targeted by the statin pharmaceutical drugs, comparison of the effects of Mg2+ on lipoproteins with those of the statin drugs is warranted.
A. Rosanoff and M.S. Seelig of the, State University of New York, Downstate Medical Center explained, "Formation of cholesterol in blood, as well as of cholesterol required in hormone synthesis, and membrane...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.